Anti-Candida sp.(CAND-0869)
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 250µg |
| Isotype : | Rabbit IgG1 |
| Purification : | Purity: >=90% Preparation: This monoclonal antibody is purified by protein A chromatography or sequential differential precipitations. |
| Content : | Concentration: >=1.0 mg/ml Formulation: Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
| Storage condition : | This purified antibody is stable when stored at 2-8°C.?Do not freeze. |
Specificity: Anti-Candida (Clone CAND-0869) is specific for several Candida species: C. albicans (10 strains), C. parapsillosis, C. glabrata, C. tropicales & C. auris. It is not reactive with C. krusei, Aspergillus, Coccidioides, Histoplasma, Blastomyces, Paracoccidioides, Penicillium notatum, Mucor, Saccharomyces cerevisiae, and Pichia pastoris.
Background: Candida species are opportunistic fungal pathogens commonly associated with healthcare-associated infections (HAIs), particularly in immunocompromised and critically ill patients. Candida infections, also known as candidiasis or yeast infections, can manifest as a variety of clinical syndromes, including bloodstream infections, urinary tract infections, surgical site infections, and candidemia. The most frequently isolated species in the context of HAIs are Candida albicans, followed by non-albicans species like Candida glabrata, Candida parapsilosis, and Candida tropicalis. Risk factors for Candida HAIs include the use of broad-spectrum antibiotics, central venous catheterization, prolonged hospitalization, and immunosuppressive therapies. Candida species have the ability to form biofilms on medical devices, further complicating treatment and facilitating their persistence in healthcare environments. Due to the rising incidence of multidrug-resistant Candida strains, early diagnosis, appropriate antifungal therapy, and infection control measures are critical to effectively manage Candida-related HAIs and improve patient outcomes.
ELISA: 1:20-1:200,IFA: 1:10-1:50
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
